Back to Journals » Lung Cancer: Targets and Therapy » Volume 12

Lung Cancer: Targets and Therapy


Archive: Volume 12, 2021

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond

Fitzpatrick O, Naidoo J

Lung Cancer: Targets and Therapy 2021, 12:123-131

Published Date: 2 November 2021

Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer

Azar I, Alkassis S, Fukui J, Alsawah F, Fedak K, Al Hallak MN, Sukari A, Nagasaka M

Lung Cancer: Targets and Therapy 2021, 12:103-114

Published Date: 7 October 2021

An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece

Mountzios G, Lampaki S, Koliou GA, Vozikis A, Kontogiorgos I, Papantoniou P, Koufaki MI, Res E, Boutis A, Christopoulou A, Pastelli N, Grivas A, Aravantinos G, Lalla E, Oikonomopoulos G, Koumarianou A, Spyratos D, Bafaloukos Snr D, Rigakos G, Papakotoulas P, Fountzilas G, Linardou H

Lung Cancer: Targets and Therapy 2021, 12:93-102

Published Date: 30 August 2021

An Update on the Use of Exhaled Breath Analysis for the Early Detection of Lung Cancer

Peled N, Fuchs V, Kestenbaum EH, Oscar E, Bitran R

Lung Cancer: Targets and Therapy 2021, 12:81-92

Published Date: 16 August 2021

Targeting AXL in NSCLC

Zaman A, Bivona TG

Lung Cancer: Targets and Therapy 2021, 12:67-79

Published Date: 10 August 2021

Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib

Tan AC, Loh TJ, Kwang XL, Tan GS, Lim KH, Tan DSW

Lung Cancer: Targets and Therapy 2021, 12:11-20

Published Date: 18 March 2021